Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes
Abstract
The DNA hypomethylating agents (HMA) azacitidine (AZA) and decitabine (DAC) improve survival and transfusion independence in myelodysplastic syndrome (MDS) and enable a low intensity cytotoxic treatment for aged AML patients unsuitable for intensive chemotherapy, particularly in combination with novel agents. The proposed mechanism of AZA and DAC relies on active DNA replication and therefore patient responses are only observed after multiple cycles of treatment. Although extended dosing may provide the optimal scheduling, the reliance of injectable formulation of the drug limits it to intermittent treatment. Recently, an oral formulation of AZA demonstrated significantly improved patient relapse free survival (RFS) and overall survival (OS) when used as maintenance after chemotherapy for AML. In addition, both DAC and AZA were found to be highly effective to improve survival in elderly patients with AML through combination with other drugs. These recent exciting results have changed the therapeutic paradigm for elderly patients with AML. In light of this, we review current knowledge on HMA mechanism of action, clinical trials exploring dosing and scheduling, and recent HMA combination therapies to enhance efficacy.Keywords
Funding Information
- Celgene
This publication has 64 references indexed in Scilit:
- Survival for older patients with acute myeloid leukemia: a population-based studyHaematologica, 2012
- A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyHaematologica, 2011
- Equitoxic Doses of 5-Azacytidine and 5-Aza-2′Deoxycytidine Induce Diverse Immediate and Overlapping Heritable Changes in the TranscriptomePLOS ONE, 2010
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesPLOS ONE, 2010
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid LeukemiaCancer Cell, 2010
- Human DNA methylomes at base resolution show widespread epigenomic differencesNature, 2009
- Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profilingHaematologica, 2009
- p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damageOncogene, 2008
- The Epigenomics of CancerCell, 2007
- A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promotersProceedings of the National Academy of Sciences, 2006